menu
    • menu
    [{"orgOrder":0,"company":"Harvard Stem Cell Institute","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"CRISPR\/Cas9 genome","moa":"","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"Harvard Stem Cell Institute","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Harvard Stem Cell Institute \/ Sarepta Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Harvard Stem Cell Institute \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"Altay Therapeutics","sponsor":"SOLVE FSHD","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","date":"September 2022","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"DUX4 expression","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"Altay Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Altay Therapeutics \/ SOLVE FSHD","highestDevelopmentStatusID":"2","companyTruncated":"Altay Therapeutics \/ SOLVE FSHD"},{"orgOrder":0,"company":"L2P Research","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Musculoskeletal","country":"","productType":"Cell and Gene therapy","date":"October 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"L2P Research","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"L2P Research \/ National Institutes of Health","highestDevelopmentStatusID":"2","companyTruncated":"L2P Research \/ National Institutes of Health"},{"orgOrder":0,"company":"CytoMed Therapeutics","sponsor":"Sengkang General Hospital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Musculoskeletal","country":"","productType":"Cell and Gene therapy","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"Mesenchymal Stem Cell Therapy","moa":"","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"CytoMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"CytoMed Therapeutics \/ Sengkang General Hospital","highestDevelopmentStatusID":"2","companyTruncated":"CytoMed Therapeutics \/ Sengkang General Hospital"},{"orgOrder":0,"company":"Relation Therapeutics","sponsor":"DCVC","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Musculoskeletal","country":"","productType":"Undisclosed","date":"March 2024","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"Relation Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Relation Therapeutics \/ DCVC","highestDevelopmentStatusID":"2","companyTruncated":"Relation Therapeutics \/ DCVC"},{"orgOrder":0,"company":"Genflow Biosciences","sponsor":"Revatis SA","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Musculoskeletal","country":"","productType":"Cell and Gene therapy","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"Genflow Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Genflow Biosciences \/ Revatis SA","highestDevelopmentStatusID":"2","companyTruncated":"Genflow Biosciences \/ Revatis SA"},{"orgOrder":0,"company":"Genflow Biosciences","sponsor":"Government of Wallonia","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Musculoskeletal","country":"","productType":"Cell and Gene therapy","date":"May 2024","year":"2024","type":"Funding","leadProduct":"Muscle Progenitor Cells","moa":"","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"Genflow Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Genflow Biosciences \/ Government of Wallonia","highestDevelopmentStatusID":"2","companyTruncated":"Genflow Biosciences \/ Government of Wallonia"}]

    Find Novel Musculoskeletal Drugs in Discovery

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Genflow Biosciences

                            United Kingdom arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Genflow Biosciences

                            United Kingdom arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Muscle Progenitor Cells

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Discovery

                            Sponsor : Government of Wallonia

                            Deal Size : $0.4 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Genflow Biosciences PLC Announces Receipt of Grant Funding

                            Details : The funding will be used to support the Sarcopenia project which focuses on the development of muscle progenitor cells which will be loaded with Genflow's proprietary SIRT6 for sarcopenia.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 30, 2024

                            Lead Product(s) : Muscle Progenitor Cells

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Discovery

                            Sponsor : Government of Wallonia

                            Deal Size : $0.4 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Relation Therapeutics

                            United Kingdom arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Relation Therapeutics

                            United Kingdom arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Discovery

                            Sponsor : DCVC

                            Deal Size : $60.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Relation Therapeutics Secures $35 Million Seed Financing Led by DCVC and NVentures

                            Details : The net proceeds will enable Relation to advance its osteoporosis pipeline towards the clinicbe and to accelerate company's discovery of novel biology, targets and medicines.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 14, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Discovery

                            Sponsor : DCVC

                            Deal Size : $60.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CytoMed Therapeutics

                            Singapore arrow
                            Aquaexpo 2024
                            Not Confirmed

                            CytoMed Therapeutics

                            Singapore arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mesenchymal Stem Cell Therapy

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Discovery

                            Sponsor : Sengkang General Hospital

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            CytoMed Therapeutics Collaborates with Singapore Hospital for Stem Cell Research

                            Details : A collaboration aims to prove the concept of an injectable cartilage regeneration therapy using umbilical cord-derived mesenchymal stem cells for knee injuries.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 04, 2024

                            Lead Product(s) : Mesenchymal Stem Cell Therapy

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Discovery

                            Sponsor : Sengkang General Hospital

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Genflow Biosciences

                            United Kingdom arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Genflow Biosciences

                            United Kingdom arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Discovery

                            Sponsor : Revatis SA

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Genflow Partners with Revatis and EXO Biologics on Aging Research

                            Details : This collaborative effort aims to expand and diversify Genflow's research pipeline for conditions such as Sarcopenia, the progressive loss of muscle mass and function associated with ageing.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 18, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Discovery

                            Sponsor : Revatis SA

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            L2P Research

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed

                            L2P Research

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Discovery

                            Sponsor : National Institutes of Health

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            L2P Research Labs Awarded NIH SBIR Grant for Arthritis, Musculoskeletal and Skin Diseases Research

                            Details : This grant will explore a cell therapy approach for the treatment of osteoarthritis via delivery of human mesenchymal stem cells (MSC) and adipose-derived stem cells (ASC) in the form of three-dimensional hydrogels.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 27, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Discovery

                            Sponsor : National Institutes of Health

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Altay Therapeutics

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Altay Therapeutics

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Discovery

                            Sponsor : SOLVE FSHD

                            Deal Size : $3.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            SOLVE FSHD Invests US$3 Million in Altay Therapeutics

                            Details : The investment will support Altay Therapeutics’ unique approach to finding an inhibitor of DUX4, a key transcription factor implicated in FSHD, that could provide an effective disease-modifying treatment.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 21, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Discovery

                            Sponsor : SOLVE FSHD

                            Deal Size : $3.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Harvard Stem Cell Institute

                            Country arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Harvard Stem Cell Institute

                            Country arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CRISPR/Cas9 genome

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Discovery

                            Sponsor : Sarepta Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Muscular Dystrophy Collaboration Aims to Correct Muscle Stem Cells’ DNA

                            Details : As per collaboration agreement, the project aims to use in-vivo genome editing, in mouse models of DMD, to fully and precisely restore the function of the dystrophin protein.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 13, 2020

                            Lead Product(s) : CRISPR/Cas9 genome

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Discovery

                            Sponsor : Sarepta Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth